Linked Life Data

11505537

Source:http://linkedlifedata.com/resource/pubmed/id/11505537

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2001-8-16
pubmed:abstractText
Combined antiandrogen therapy (complete androgen blocking) implies surgical or chemical castration in combination with antiandrogen therapy. Both sources of androgens are thus blocked in patients with locally disseminated prostatic cancer. The purpose of this study was to evaluate the efficiency of bikalutamide (150 mg) monotherapy. The study was carried out in 58 patients with prostatic cancer (stages T3-T4) divided into 2 groups: 1) bikalutamide monotherapy (150 mg daily) and 2) bikalutamide (50 mg daily) + bilateral orchidectomy. All patients were examined before and 3, 6, 12, 18, and 24 months after the beginning of therapy. The efficiency of non-steroid antiandrogen was higher in group 1. The mean level of prostate-specific antigen in this group decreased to 10.6 ng/ml by 24 months, while in group 2 to 25.3 ng/ml. Hence, bicalutamide was effective, safe, and well tolerated in our study, and is therefore recommended as monotherapy for patients with disseminated forms of prostatic cancer.
pubmed:language
rus
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1728-2985
pubmed:author
pubmed:issnType
Print
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
26-8
pubmed:dateRevised
2008-2-21
pubmed:meshHeading
pubmed:articleTitle
[Bicalutamide monotherapy of patients with disseminated forms of prostatic cancer].
pubmed:publicationType
Journal Article, English Abstract